Mattias Ekstedt
Overview
Explore the profile of Mattias Ekstedt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
5212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Byenfeldt M, Kihlberg J, Nasr P, Gronlund C, Lindam A, Bartholoma W, et al.
Eur Radiol
. 2024 Mar;
34(9):5989-5999.
PMID: 38459346
Objectives: To evaluate the diagnostic performance of ultrasound guided attenuation parameter (UGAP) for evaluating liver fat content with different probe forces and body positions, in relation to sex, and compared...
12.
McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg J, Bugianesi E, et al.
PLoS One
. 2024 Feb;
19(2):e0299487.
PMID: 38421999
Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to...
13.
Shang Y, Akbari C, Dodd M, Nasr P, Vessby J, Rorsman F, et al.
Gut
. 2024 Feb;
73(11):e30.
PMID: 38408839
No abstract available.
14.
Yang W, Ebrahimi F, Romeo S, Holmer M, Vessby J, Ekstedt M, et al.
Liver Int
. 2024 Feb;
44(5):1253-1264.
PMID: 38385564
Background & Aims: Previous studies have suggested an increased risk of major adverse liver outcomes (MALO) in relatives of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, granular and...
15.
Akbari C, Dodd M, Stal P, Nasr P, Ekstedt M, Kechagias S, et al.
JHEP Rep
. 2024 Jan;
6(2):100915.
PMID: 38293684
Background & Aims: Long-term studies of the prognosis of NAFLD are scarce. Here, we investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients with...
16.
Nasr P, Wester A, Ekstedt M, Strandberg R, Kechagias S, Shang Y, et al.
Clin Gastroenterol Hepatol
. 2024 Jan;
22(5):1048-1057.e2.
PMID: 38237695
Background & Aims: Alcohol overconsumption is a risk factor for disease progression in patients with presumed metabolic dysfunction-associated steatotic liver disease (MASLD). How commonly this occurs and how it affects...
17.
Nasr P, Forsgren M, Balkhed W, Jonsson C, Dahlstrom N, Simonsson C, et al.
BMC Gastroenterol
. 2023 Dec;
23(1):454.
PMID: 38129794
Background: Liver cirrhosis, the advanced stage of many chronic liver diseases, is associated with escalated risks of liver-related complications like decompensation and hepatocellular carcinoma (HCC). Morbidity and mortality in cirrhosis...
18.
Herrgardh T, Simonsson C, Ekstedt M, Lundberg P, Stenkula K, Nyman E, et al.
Diabetol Metab Syndr
. 2023 Dec;
15(1):250.
PMID: 38044443
Background: The increased prevalence of insulin resistance is one of the major health risks in society today. Insulin resistance involves both short-term dynamics, such as altered meal responses, and long-term...
19.
Pavlides M, Mozes F, Akhtar S, Wonders K, Cobbold J, Tunnicliffe E, et al.
Contemp Clin Trials
. 2023 Oct;
134:107352.
PMID: 37802221
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome with global prevalence reaching epidemic levels. Despite the high disease burden in the population only a small...
20.
Knochel J, Bergenholm L, Ibrahim E, Kechagias S, Hansson S, Liljeblad M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(12):2038-2049.
PMID: 37750001
Disease progression in nonalcoholic steatohepatitis (NASH) is highly heterogenous and remains poorly understood. Fibrosis stage is currently the best predictor for development of end-stage liver disease and mortality. Better understanding...